Skip to main content

SMART LASERS COULD MAKE CANCER BIOPSIES PAINLESS

Image result for LASERS COULD MAKE CANCER BIOPSIES PAINLESS

EAST LANSING, Mich. — Biopsies in the future may be painless and noninvasive, thanks to smart laser technology being developed at Michigan State University.
To test for skin cancer, patients today must endure doctors cutting away a sliver of skin, sending the biopsy to a lab and anxiously awaiting the results. Using laser microscopes that deploy rapid, ultra-short pulses to identify molecules, doctors may soon have the tools to painlessly scan a patient’s troublesome mole and review the results on the spot, said Marcos Dantus.
The results touting this new molecule-selective technology can be found in the current issue of Nature Photonics, which Dantus co-authored with Sunney Xie of Harvard University.
“Smart lasers allow us to selectively excite compounds – even ones with small spectroscopic differences,” said Dantus. “We can shape the pulse of the lasers, excite one compound or another based on their vibrational signatures, and this gives us excellent contrast.”
In the past, researchers could approach this level of contrast by introducing fluorescent compounds. With the breakthrough using stimulated Raman scattering microscopy, fluorescent markers are unnecessary.
“Label-free molecular imaging has been the holy grail in medicine,” Dantus said. “SRS imaging gives greater specificity and the ability to map a particular chemical species in the presence of an interfering species, such as cholesterol in the presence of lipids.”
Additional potential applications include allowing researchers to closely examine how compounds penetrate skin and hair. Smart lasers also can better identify how drugs penetrate tissue and how drugs and tissue interact, thus mitigating the chances of potential side effects and helping reduce the time required to bring new drugs to market.

Comments

Post a Comment

Popular posts from this blog

HYFRECATORS AND INTERFERENCE WITH IMPLANTABLE CARDIAC DEVICES

Investigation of Hyfrecators and They are In Vitro Interference with Implantable Cardiac Devices CHRISTOPHER WEYER, DO,* RONALD J. SIEGLE, MD,†‡ AND GUILLAUME GIRARD P. ENG, EMI-EMC§ BACKGROUND Guidelines exist for minimizing potential electromagnetic interference (EMI) with electrosurgical equipment in patients with cardiac rhythm management (CRM) devices. These guidelines encompass all electrosurgical devices but are not specific for hyfrecators. OBJECTIVE To investigate the potential interference of CRM devices by hyfrecators. MATERIALS AND METHODS Using a collagen-based saline gel, three implantable pulse generators (pacemakers) and three implantable cardioverter defibrillators were tested to measure the EMI from two commonly used hyfrecators. The six devices were tested using the hyfrecator under normal use settings and on maximum power. RESULTS Hyfrecators did not interfere with defibrillators and affected pacemakers only when used in close proximity to the devi...
Post a Comment
Read more

NEW DRUG THERAPY FOR BCC

Genentech Submits New Drug Application to FDA for Vismodegib for Rare Form of Advanced Skin Cancer Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company has submitted a New Drug Application for vismodegib to the U.S. Food and Drug Administration (FDA) for the treatment of people with advanced basal cell carcinoma (BCC) for whom surgery is considered inappropriate. Vismodegib is an investigational, oral, targeted medicine designed to selectively inhibit signaling in the Hedgehog pathway, which is implicated in more than 90 percent of BCC cases. BCC is the most common type of skin cancer, which is generally considered curable by surgery. However, when it advances, BCC can cause disfiguring and debilitating effects and can ultimately be life-threatening. “We are excited by the pivotal study results that showed vismodegib substantially reduced tumor size or healed lesions for people with this rare skin cancer, which has no approved ...
Post a Comment
Read more

TRANSACTION AND MELANOMA SURVIVAL

The rate of melanoma transaction with various biopsy techniques and the influence of tumor transaction on patient survival Mohsin Mir, MD, C. Stanley Chan, MD, Farhan Khan, MD, MBA, Bhuvaneswari Krishnan, MD, Ida Orengo, MD, and Theodore Rosen, MD Houston, Texas Background: Depth of melanoma invasion is critical because it dictates patient treatment and prognosis. Recent reports indicate melanoma transection with initial biopsy does not impact patient survival; however, tumor transaction can lead to misdiagnosis and inaccurate staging. Objective: This study assessed the rate of melanoma transaction with various biopsy techniques and the impact of tumor transaction on patient survival. Methods: We conducted a retrospective review of all melanoma cases at our institution between 2000 and 2008. Of the 490 melanoma cases identified, 479 met inclusion criteria for the study. The transaction rates of biopsy techniques were determined. Cases of transected ...
Post a Comment
Read more